In COVID-19 clinical update #113, Dr. Griffin discusses tocilizumab use in hospitalized Patients, IL-6 inhibitors and mortality, Baricitinib in hospitalized patients, post-infection neurological sequelae, comparative effectiveness of Pfizer and Moderna vaccines, phase 2/3 study of Paxlovid, infection relapse following Paxlovid, pre-hospital administration of Remdesivir, and hospitalization with different variants.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Timing of Tocilizumab Use in Hospitalized Patients (NIH)
• Interleukin-6 inhibitors reduce mortality (European Journal of Internal Medicine) 
• Treatment Effect of Baricitinib on Hospitalized Patients (IDSA)
• Post Infection Neurological Sequelae (Res Square)
• Comparative Effectiveness of Pfizer and Moderna Vaccines (Nature Commun)
• Results from Phase 2/3 Study of Paxlovid (Pfizer) 
• Infection Relapse Following Suppression by Paxlovid (Res Square)
• Update on Paxlovid Usage (FDA)
• Availability and Use of Treatments in Outpatients (CDC)
• Pre-Hospital Administration of Remdesivir (IDSA)
• Remdesivir and three other drugs for Hospitalized Patients (Lancet)
• Guidelines on Usage of Anticoagulants (Am Soc Hematol)
• Different Variants Hospitalization and Morality (Res Square)
• Contribute to FIMRIC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 897
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]